Kwality Pharmaceuticals Ltd.
Snapshot View

381.20 +18.15 ▲5.0%

20 May 2022, 04:01:00 PM
Volume: 4,000

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.kwalitypharma.com
Market Cap 392.58 Cr.
Enterprise Value(EV) 430.96 Cr. 2021-03
Financial Indicators
Earnings per share (EPS) 14.60 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 26.12 Trailing Twelve Months Ending 2021-03
Industry PE 29.26 Trailing Twelve Months Ending 2021-03
Book Value / Share 58.16 Trailing Twelve Months Ending 2021-03
Price to Book Value 6.55 Calculated using Price: 381.20
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.04 Cr. 10,376,198 Shares
FaceValue 10
Company Profile

The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.

The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization). 

Milestones

  • 1983: Incorporation of the company on May 04, 1983.
  • 2007: Received ISO Certification.
  • 2008: Commencement of new manufacturing unit at Jassur in Himachal Pradesh.
  • 2009: Received status of Star Export House Certificate.
  • 2012: Turnover increased by 75%.
  • 2013: Incorporation of Subsidiary Company in Africa.
  • 2014: Received WHO certification.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+5.00%
1 Week
+3.73%
1 Month
-23.57%
3 Month
-20.28%
6 Month
-53.61%
1 Year
+272.45%
2 Year
+950.14%
5 Year
+679.55%
10 Year
8 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 5.26 4.43 6.54 14.41 16.51 23.13 20.10 28.21
Return on Capital Employed (%) 10.52 9.58 12.34 19.64 19.19 21.91 18.49 26.36
Return on Assets (%) 2.66 2.21 2.90 5.37 5.29 7.50 6.90 9.97

Balance Sheet View Details

Particulars 8 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 18 19 22 26 30 37 46 61
Non Curr. Liab. 2 1 3 4 5 8 20 28
Curr. Liab. 15 17 27 42 62 61 68 78
Minority Int. 0 0 0 -1 -1 -1 -1 -1
Equity & Liab. 35 37 51 71 96 105 132 166
Non Curr. Assets 13 13 13 18 21 30 43 60
Curr. Assets 22 24 38 53 75 75 89 106
Misc. Exp. not W/O 0 0 0 0
Total Assets 35 37 51 71 96 105 132 166

Profit Loss View Details

Particulars 8 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 60 52 74 98 137 166 139 262
Other Income 0 0 0 1 1 1 4 2
Total Income 60 53 75 100 138 167 143 264
Total Expenditure -56 -49 -69 -89 -126 -151 -125 -233
PBIDT 4 4 5 10 12 16 18 30
Interest -1 -1 -1 -2 -2 -2 -3 -3
Depreciation -1 -1 -2 -3 -3 -3 -4 -6
Taxation -1 -1 -1 -2 -3 -3 -3 -6
Exceptional Items
PAT 1 1 1 3 4 8 8 15
Minority Interest 0 0 0 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 1 1 2 3 5 8 8 15
Adjusted EPS 1 1 2 3 4 7 8 15

Cash Flow View Details

Particulars 8 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -1 1 -3 4 -1 14 6 27
Cash Fr. Inv. -3 -1 -2 -7 -6 -12 -18 -23
Cash Fr. Finan. 3 1 6 5 5 -2 12 1
Net Change -1 1 0 2 -1 0 0 4
Cash & Cash Eqvt 1 1 1 3 2 1 2 6

Shareholding Pattern View Details

9 Qtrs 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 50.14 50.14 50.14 51.52 51.52 54.13 54.24 54.24 54.43
Public 49.86 49.86 49.86 48.48 48.48 45.87 45.76 45.76 45.57
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 18 May 2022
Board Meeting Intimation for INTIMATION OF BOARD MEETING TO CONSIDER THE STANDALONE & CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND FINANCIAL YEAR ENDED ON 31ST MARCH 2022
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve Pursuant to regulation 29 of the SEBI (Listing obligations and disclosure requirements) Regulations 2015 we hereby inform the stock exchange that the meeting of board of directors of the company is scheduled to be held on Saturday May 28 2022 at 5:00 p.m. at VILLAGE NAGKALAN MAJITHA ROAD AMRITSAR to consider and approve the standalone & consolidated audited financial results for the half year and financial year ended on 31st March 2022.
Wed, 20 Apr 2022
Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended On March 31 2022
Pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the Certificate issued by Practicing Company Secretary for the year ended 31st March 2022.
Tue, 12 Apr 2022
Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P /2018/144 Dated 26Th November 2018- Fund Raising By Issuance Of Debt Securities By Large Corporate (LC)
With reference to the SEBI Circular dated 26th November 2018 on above mentioned subject we confirm that " Kwality Pharmaceuticals Limited" is not falling under Large Corporate Category as on 31st March 2022.

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%